Drugs / VSV-GP154
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05846516 | May 2023 → Mar 2027 expected | pancreatic ductal adenocarcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSV-GP154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05846516 ↗ |
| Modality | Vaccine | “Heterologous Prime Boost Vaccination (ATP150/ATP152/ATP162, VSV-GP154)” NCT05846516 ↗ |